What Does a Positive Surgical Margin Mean After Prostatectomy?
A positive surgical margin means that cancer cells touch the inked cut surface of the prostate removed at radical prostatectomy. It is an important finding, but it does not by itself prove that cancer remains in the body, predict an inevitable recurrence or mean that radiotherapy must start immediately. The first postoperative PSA result, tumour grade and stage, margin details and the person's health all affect the next step. The CAP pathology protocol 1 defines the reporting terms; the EAU treatment guideline 2 places them in the treatment decision.
How does the pathologist identify a positive margin?
The outside cut surface of the specimen is marked with ink. Under the microscope, a margin is positive when tumour cells touch that ink. A negative margin means no such contact is seen. A report may also describe the site, length or extent and whether more than one area is involved. A tumour close to the ink is not necessarily the same as tumour on the ink. If the wording is unclear, ask for an explanation rather than making a treatment decision from a single label. Our guide to the complete prostatectomy pathology report explains the other fields. Sources: 1.
Does a positive margin mean spread beyond the prostate?
No. Stage pT3a describes extension beyond the gland; a positive margin describes the cut edge of the removed specimen. They may occur together, but are distinct findings. A positive margin does not establish lymph node involvement or distant metastasis. The pathological stage, Gleason score and ISUP Grade Group, seminal vesicle status and any node findings must be read together. Margin positivity can increase the chance of PSA recurrence, but it cannot be turned into a certain outcome for an individual. Sources: 1 5.
Why is the first PSA test so important?
PSA is expected to fall to an undetectable level after the prostate has been removed. The EAU notes that this is generally expected by about two months; testing too early can mislead. If PSA becomes undetectable, a positive margin alone does not call for identical extra treatment in everyone. Regular PSA surveillance is planned. PSA that remains detectable from the start is different from PSA that rises after becoming undetectable and needs its own assessment. One tiny ultrasensitive result should be interpreted with repeat measurement and the trend, not in isolation. See the EAU follow-up guidance 3 and the postoperative PSA guide.
Radiotherapy now or surveillance with early salvage treatment?
Adjuvant radiotherapy is given soon after surgery while PSA is undetectable. Salvage radiotherapy is considered when PSA becomes detectable or rises. In the studied populations, the RADICALS-RT trial 6 and the prospectively planned ARTISTIC meta-analysis 9 did not show a clear advantage for routine immediate radiotherapy over close PSA monitoring with early salvage treatment when needed. Immediate treatment can add urinary side effects. These results should not be applied without qualification to every very high-risk subgroup or to someone whose PSA never becomes undetectable. Selected patients with several adverse features may still discuss adjuvant treatment. The urologist and, when appropriate, radiation oncologist should review that balance together.
What happens if PSA rises?
First confirm the trend and review its speed alongside the full pathology report. Imaging, including PSMA PET, may help when it would change a decision; a negative scan at low PSA cannot rule out microscopic disease. The AUA/ASTRO/SUO salvage guideline 4 states that salvage radiotherapy works better at lower PSA levels. It recommends offering it to appropriate candidates when PSA is no higher than 0.5 ng/mL and allows discussion below 0.2 ng/mL in patients at high risk. These are clinical decision points, not instructions to start treatment on your own. Stage, grade, PSA course, imaging, life expectancy and possible urinary, bowel and sexual effects all matter. For treatment context, see robotic radical prostatectomy and prostate cancer care.
Questions to take to your appointment
Ask where the positive margin is and how extensive it is; what the Grade Group, pT stage and node findings show; when and how the first PSA will be measured; and how the plan differs for undetectable, persistently detectable and later rising PSA. Recovery of urinary control and sexual function also belongs in the discussion about radiotherapy timing. A positive margin is a risk marker to interpret carefully, not a verdict about one person's future. Sources: 2 3 4.
Do the margin's location, length and number of sites matter?
The report may identify the area of the prostate involved, whether one or several sites are positive, and the measured length. A systematic review of 31 studies found associations between longer or multiple positive margins and PSA recurrence. Most underlying studies were observational, however. Margin length alone cannot tell a patient whether radiotherapy is needed. Pathological stage, ISUP Grade Group and the Gleason pattern at the margin can alter the interpretation. A research cutoff such as 3 mm is not a universal treatment threshold. If your report does not state the extent, ask whether that detail would change the discussion. Sources: 1 5.
Why can the same margin result lead to different plans?
An organ-confined, lower-grade tumour with a short focal margin presents a different picture from pT3b disease, higher grade, several involved sites or positive lymph nodes. Whether the first PSA is undetectable or persistently detectable matters as well. Biochemical recurrence, visible metastasis and death from prostate cancer are different outcomes. A study linking a feature to more PSA recurrence does not prove the same increase in the other outcomes for every individual. The pathology, PSA course, overall health and treatment preferences must be considered together. Sources: 2 4 5.
What does the comparative evidence actually show?
Longer follow-up of RADICALS-RT did not show a clear distant-metastasis or overall-survival advantage for routine adjuvant radiotherapy over observation with salvage treatment when needed; urinary and bowel effects were greater with immediate treatment. RAVES reported similar biochemical control and less genitourinary toxicity in the early-salvage group, but did not meet its prespecified statistical non-inferiority criterion. GETUG-AFU 17 specifically enrolled men with positive margins and pT3–4, pN0/pNx disease; both arms received six months of hormone treatment. It showed no event-free-survival benefit from immediate radiotherapy, but early closure limited its power. ARTISTIC combines these trials rather than adding a separate group of patients. None of these findings removes the need to assess an individual with persistent PSA or several very high-risk features. Sources: 6 7 8 9.
A practical distinction for PSA tests and imaging
| PSA pattern | Main point to discuss |
|---|---|
| First appropriately timed PSA is undetectable | Arrange PSA surveillance tailored to pathology; discuss any immediate treatment in the context of overall risk and side effects. Sources: 2 3. |
| PSA remains detectable from the first test | Check timing and repeat the result; assess disease extent and discuss salvage options promptly. Sources: 2 4. |
| PSA fell and later rises | Confirm the trend, review risk and imaging when useful, and discuss salvage radiotherapy at a low PSA in appropriate patients. Sources: 3 4. |
The EAU's general follow-up schedule uses PSA testing about every six months for the first three years and yearly thereafter; individual risk can change it. Routine scans are generally not helpful without rising PSA or symptoms. PSMA PET is considered when a result might change care, and a negative study at low PSA cannot exclude microscopic disease. Sources: 2 3 4.
How should potential treatment harms be weighed?
Radiotherapy can target possible microscopic disease in the prostate bed, but may affect urinary control, bowel function and sexual health. Whether to add hormone treatment to salvage radiotherapy is another risk-dependent decision. Existing continence, other health conditions and the patient's priorities belong in this discussion. The goal is to avoid delaying useful treatment while sparing patients an intervention they may never need. Sources: 2 4 6.
Frequently asked questions
Does a positive margin prove cancer was left behind?
No. Tumour cells reached the inked edge of the removed tissue, but this does not directly prove that viable tumour remains in the body. PSA and the rest of the pathology guide follow-up. Source: 1 2.
Must I have radiotherapy immediately?
Not automatically. With undetectable PSA, surveillance and early salvage radiotherapy if needed is an option for many people. Several high-risk findings or persistent PSA can change the discussion. Source: 2 6 9.
Does it mean I need another operation?
A repeat prostatectomy is generally not done solely because of a positive margin. The PSA pattern and overall risk are assessed first; radiotherapy and other options may then be discussed. Source: 2 4.
Is a margin longer than 3 mm an automatic treatment trigger?
No. Length can help with risk assessment, but the 3 mm boundary used in research groups is not a treatment rule for everyone. Stage, grade, other margin features and PSA matter. Source: 5.
Does a PSA of 0.01 ng/mL mean recurrence?
A single very low ultrasensitive result is not enough. The assay, earlier values and trend on repeat testing need interpretation. Source: 3.
How long is follow-up needed when PSA is undetectable?
Follow-up can continue for years. The EAU generally describes PSA about every six months for three years and annually after that; personal risk and life expectancy can change the plan. Source: 3.
Does a negative PSMA PET make radiotherapy unnecessary?
No. Microscopic disease may not be visible at low PSA. The scan is interpreted with PSA behaviour and pathology; a negative image alone does not settle the decision. Source: 2 4.
Does a positive margin prove the operation was performed incorrectly?
No. Tumour location and extent, and the balance between adequate removal and preserving function, can affect the result. Surgical quality cannot be judged from one pathology term alone. Source: 1 2.
Sources
-
College of American Pathologists. Protocol for the Examination of Radical Prostatectomy Specimens [Internet]. Available from: https://www.cap.org/wp-content/uploads/protocols/Prostate_4.3.0.0.REL_CAPCP.pdf?download=true
Source details and use in the article
Version: 4.3.0.0
Access checked: 26 October 2026Use in this article: Inked margin and pathological stage definitions.Limit: A pathology protocol is not a treatment guideline. -
European Association of Urology. EAU Guidelines on Prostate Cancer: Treatment [Internet]. Available from: https://uroweb.org/guidelines/prostate-cancer/chapter/treatment
Source details and use in the article
Access checked: 26 October 2026Use in this article: Adjuvant/salvage therapy, persistent PSA and decision framework.Limit: Recommendations require individual risk assessment. -
European Association of Urology. EAU Guidelines on Prostate Cancer: Follow Up [Internet]. Available from: https://uroweb.org/guidelines/prostate-cancer/chapter/followup
Source details and use in the article
Access checked: 26 October 2026Use in this article: Postoperative PSA timing, follow-up and imaging.Limit: Follow-up intervals vary by patient. -
AUA/ASTRO/SUO. Salvage Therapy for Prostate Cancer: Guideline Part I. J Urol, 2024 [Internet]. Available from: https://auau.auanet.org/sites/default/files/media/2025-02/Salvage%20Therapy%20for%20Prostate%20Cancer%20AUAASTROSUO%20Guideline%20Part%20I.pdf
Source details and use in the article
DOI: 10.1097/JU.0000000000003892
Access checked: 26 October 2026Use in this article: Early salvage treatment at low PSA and shared decisions.Limit: Numbers are not automatic treatment triggers. -
Guo H et al. The impact of positive surgical margin parameters and pathological stage on biochemical recurrence after radical prostatectomy. PLoS One, 2024 [Internet]. Available from: https://pubmed.ncbi.nlm.nih.gov/38990870/
Source details and use in the article
Use in this article: Associations of margin length, focality, grade and stage with PSA recurrence.Limit: Mostly observational studies cannot predict one patient's outcome with certainty. -
Parker CC et al. Timing of radiotherapy after radical prostatectomy: long-term outcomes in RADICALS-RT. Ann Oncol, 2024 [Internet]. Available from: https://pubmed.ncbi.nlm.nih.gov/38583574/
Source details and use in the article
Use in this article: Long-term RADICALS-RT comparison and harms.Limit: The earlier 2020 report is the same trial, not independent evidence. -
Kneebone A et al. Adjuvant radiotherapy versus early salvage radiotherapy after prostatectomy (RAVES). Lancet Oncol, 2020 [Internet]. Available from: https://pubmed.ncbi.nlm.nih.gov/33002437/
Source details and use in the article
Use in this article: RAVES comparison of adjuvant and early salvage policies.Limit: The prespecified non-inferiority criterion was not met. -
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1341-1352. doi:10.1016/S1470-2045(20)30454-X · PubMed
Source details and use in the article
Use in this article: GETUG-AFU 17 in a selected positive-margin population.Limit: Early closure and hormone therapy in both arms limit interpretation. -
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;396(10260):1422-1431. doi:10.1016/S0140-6736(20)31952-8 · PubMed · PMC
Source details and use in the article
Use in this article: Prospectively planned pooled analysis of the three trials.Limit: Contains RADICALS-RT, RAVES and GETUG-AFU 17 participants, not new independent patients.
Keep reading:
Related patient guides
How to Understand Your Pathology Report After Prostatectomy
Understand grade group, pathological stage, surgical margins and lymph node findings after radical prostatectomy.
PSA After Robotic Prostatectomy: What Do the Results Mean?
When PSA is first measured after robotic radical prostatectomy, what a detectable result means and how biochemical recurrence and salvage treatment are assessed.
What Are the Gleason Score and ISUP Grade Group?
Gleason and ISUP grades describe tumour architecture; stage and treatment choices require the whole clinical picture.